Trial reportNature medicine2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Erratum issuedAbstract readClinical Trial, Phase IIIClinical Trial, Phase IVMulticenter Study
In one paragraph
Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 143 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).Current oncology (Toronto, Ont.) · 2026Guideline
- Pooled it
- A Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD/Pneumonitis in Solid Tumors.Drug design, development and therapy · 2025Pooled it
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.Current oncology (Toronto, Ont.) · 2024Guideline
- Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer.ESMO open · 2026Trial
- Hypofractionated stereotactic radiotherapy versus whole-brain radiotherapy following brain metastasis resection: Results of the ESTRON randomized phase 2 trial.Neuro-oncology · 2025Trial
- Article
- Cerebrospinal fluid circulating tumor DNA profiling in central nervous system metastases from solid tumors: A prospective multicentre translational analysis of the BrainStorm (OncoDistinct-006) study.The journal of liquid biopsy · 2026Article
- Preclinical evaluation of trastuzumab deruxtecan in a new HER2+ leptomeningeal colonization model.Cancer letters · 2026Article
- Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.Nature reviews. Clinical oncology · 2026Review
- Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy.Breast cancer research and treatment · 2026Article
- Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma.Molecular and cellular pediatrics · 2026Article
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report.Gynecologic oncology reports · 2026Article
- Article
- Accelerating discovery: Transformative clinical trial models in neuro-oncology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.Journal of hematology & oncology · 2026Review
- Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Nadia HarbeckBreast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany. nadia.harbeck@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-9744-7372
Eva CiruelosHospital Universitario 12 de Octubre, Madrid, Spain.ORCID http://orcid.org/0000-0002-2796-1042
Guy JerusalemCHU Liège and Liège University, Liège, Belgium.ORCID http://orcid.org/0000-0002-8845-0043
Volkmar MüllerUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Naoki NiikuraTokai University School of Medicine, Kanagawa, Japan.
Giuseppe VialeDepartment of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.
Rupert BartschDivision of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria.
Christian KurzederBreast Center, University Hospital Basel, Basel, Switzerland.
Michaela J HigginsSt. Vincent's University Hospital, UCD Cancer Trials Cluster, Dublin, Ireland.
Roisin M ConnollyCancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland.ORCID http://orcid.org/0000-0003-0056-1070
Sally Baron-HayDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia.ORCID http://orcid.org/0000-0002-9748-1458
María GiónIOB-Madrid, Beata María Ana Hospital, Madrid, Spain.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Giampaolo BianchiniDepartment of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0002-6790-6267
Hans WildiersDepartment of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8990-7837
Santiago Escrivá-de-RomaníVall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Manoj PrahladanGlobal Medical Affairs, Oncology R&D, AstraZeneca, Cambridge, UK.
Helen BridgeOncology Global Medical Affairs / Payer Biometrics, AstraZeneca, Macclesfield, UK.
Nataliya Kuptsova-ClarksonPatient Safety, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Nana ScottoOncology Global Medical Affairs, AstraZeneca, Baar, Switzerland.
Sunil VermaOncology Franchise, AstraZeneca, Gaithersburg, MD, USA.
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2263-5413
DESTINY-Breast12 study group
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2
Indexed as
Brain NeoplasmsBreast NeoplasmsCamptothecinErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedAntineoplastic Agents, ImmunologicalFemaleHumansImmunoconjugatesMiddle AgedProgression-Free SurvivalProspective StudiesAntineoplastic Agents, ImmunologicalCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabtrastuzumab deruxtecan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.